Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1

Conditions

Melanoma 56Carcinoma, Non-Small-Cell Lung 53Carcinoma, Renal Cell 37Lung Neoplasms 22Neoplasm Metastasis 21Carcinoma, Hepatocellular 21Stomach Neoplasms 17Squamous Cell Carcinoma of Head and Neck 17Neoplasms 17Colorectal Neoplasms 17Carcinoma, Transitional Cell 14Adenocarcinoma Of Esophagus 13Prostatic Neoplasms 11Hodgkin Disease 11Brain Neoplasms 10Urinary Bladder Neoplasms 9Ovarian Neoplasms 8Multiple Myeloma 8Triple Negative Breast Neoplasms 7Skin Neoplasms 7Rectal Neoplasms 7Pancreatic Neoplasms 7Esophageal Neoplasms 7Colonic Neoplasms 7Clear-cell metastatic renal cell carcinoma 7Breast Neoplasms 7Sarcoma 6Carcinoma, Merkel Cell 6Carcinoma, Basal Cell 6Uveal Melanoma 5

Interventions

tremelimumab 2pembrolizumab 2Nivolumab 2Carboplatin 2poly ICLC 1osimertinib 1lenvatinib 1durvalumab 1cemiplimab 1balstilimab 1Vascular Endothelial Growth Factor A 1Peptides 1Pemetrexed 1Paclitaxel 1Ipilimumab 1Docetaxel 1Blood Specimen Collection 1Antibodies, Bispecific 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Diabetes Mellitus, Insulin-Dependent, 12 × Nivolumab × 90 days × Clear all
NCT07476326 2026-04-03

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

Biocon Limited

Phase 1 Not yet recruiting
120 enrolled
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasms

NCT07000149 2026-03-10

eVOLVE-RCC02

AstraZeneca

Phase 3 Active not recruiting
1,116 enrolled
Genitourinary

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡